Carbohydrate composition for even reaction to glucose

FIELD: food industry.

SUBSTANCE: invention relates to low-glycemic affordable carbohydrate composition. Carbohydrate composition in compliance with invention contains the following components: (i) 5-60 wt %, one or more monosaccharides, selected from monosaccharides that differ from glucose and fructose, in particular, galactose, ribose and mannose; (ii) 10-75 wt % oligosaccharides, having length of 2-20 anhydromonose units, at least half of which represents anhydroglucose remains bound in alpha-1-position with 1-, 3-, 5- or 6 positions of another anhydromonose unit, besides, component (ii) contains 10-60 wt % of one or more oligosaccharides selected from trehalulose, palatinose, turanose and leucrose; (iii) 0-75 wt %, other affordable carbohydrates. Invention also relates to food composition, containing low-glycemic carbohydrate composition and proteins and/or lipids, besides, carbohydrate composition makes 35-70 en.% of food composition. Food composition is used to treat diabetes, obesity, resistance to insulin, or for postprandial reaction to glucose.

EFFECT: carbohydrate composition makes it possible to maintain low level of glucose in blood and tissues after consumption for a long period of time and does not result in undesirable high concentrations of glucose in blood in people, who became resistant to insulin.

12 cl, 1 ex


The technical field to which the invention relates

The invention relates to carbohydrate fraction, which gives a delayed and slower release of glucose after consumption.

The level of technology

Glucose is an important energy source for cells in the body and in abundance in food ingredients. After eating starch or other diet available sources of glucose and subsequent digestion, glucose is released into the gastrointestinal tract, where it is quickly and efficiently absorbed from the intestinal cavity. This usually increases the concentration of glucose in the blood. Changes in the concentration of glucose after eating is called postprandial response to glucose (PPGR), which can be measured as the area under the curve (AUC), which represents the concentration of glucose in plasma over time. The human body strives to maintain homeostasis of glucose levels in tissue and blood in time to ensure proper functioning of all cells. One important tool for the maintenance of glucose homeostasis is the release of insulin by the pancreas when the concentration of certain nutrients, such as glucose, begins to increase. Under normal circumstances, this increases the transport of glucose into the cell and creation is glycogen using glucose and causes other metabolic changes, besides, quickly leading to lower levels of blood glucose to normal levels.

The man who does not properly respond to the released insulin, referred to as resistant to insulin. Large groups of people suffer from insulin resistance, as many sufferers are obese people people suffering from so-called metabolic syndrome (or syndrome X), diabetes and many patients in hospitals or nursing homes who have developed a temporary or more long lasting insulin resistance as the cause of their disease. Part diabetics also had insufficient capacity to increase the concentration of insulin in the blood after eating the food (called postprandial). People who suffer from insulin resistance, demonstrating pathological high postprandial response to glucose even after consumption of moderate quantities of food ingredients containing glucose. When high post-meal glucose concentrations occur relatively often and for longer periods of time, they can cause some serious health problems. Known secondary side effects that can be detected in diabetics, are problems of the cardiovascular system such as hypertension, at rocklers, poor blood flow to peripheral tissues, stroke, heart attacks, etc. as well as the problems of the kidney, in particular pathological glomerular filtration rate and a wide range of neuropathies and retinopathy, as cataract. Also found that mortality from severe illness in hospitalized patients is associated with the severity of insulin resistance.

Reducing postprandial response to glucose (PPGR) has been the subject of numerous research programmes. It was proposed many types of carbohydrates to induce low PPGR. To this end it was proposed that the inclusion of dietary fiber in the original food product, for example, viscous fibers, as gum or pectin. The disadvantage of the use of such fibers is to increase the viscosity, leading to bloating, flatulence, loss of appetite and possibly constipation, when used in liquid products in quantities that are effective.

In DE 3935906 disclosed the use of galactose for food, patients with metabolic stress, such as suffering from diabetes. There also may be other sugars such as glucose, mannose, N-acetylglucosamine, N-atsetilgalaktozamin, fucose, fructose or lactulose, although preferably galactose is at least 50% or even at least 75% of sugars. Amino acids, solii etc. also included in parenteral introduction.

In WO03/104473 disclosed galactosylceramide gidrirovannoe and negidrirovannah isomaltulose for the production of oligosaccharides, which are useful as probiotics. They should also be useful for the regulation of glycemic properties of food.

In WO04/081022 described granulometric composition containing the prebiotic isomalto-oligosaccharides obtained using transglycosylase maltose. This composition can be used for various purposes, including ingredient for baking and solution for oral rehydration.

In EP-A1229803 from Stahl also disclosed certain synthetic oligosaccharides obtained using transglycosylase that are slowly digested.

In WO 01/17370 disclosed the use of trehalose to provide food to people suffering from metabolic disorders of insulin. Trehalose replaces other sugars such as sucrose, glucose and maltose, which should mainly be missing.

The aim of the invention is the provision of a food product, effective for fast supply of glucose to the consumer and maintain clinically significant supply of glucose for a long time, do not result in undesirable high concentrations of glucose in the blood even in people stabs the x resistant to insulin.

An additional aim of the invention is the provision of food for people suffering from insulin resistance, to prevent the development of disorders resulting from prolonged and frequent high levels of glucose in the blood such as diseases resulting from products increased glycosylation (AGE), neuropathy, retinal problems and kidney problems.

Description of the invention

It was found that a combination of one or more sugars in addition to glucose and fructose, especially one or more galactose, mannose and ribose, with oligosaccharides containing glucose, in which glucose is at least partially connected not by α-1,4 linkages, is suitable as nitroglicerina composition that provides the body with glucose by slow release and delays, where the monosaccharides contribute to the availability of glucose due to metabolic conversion. Not only that, this combination has a positive effect on glycemic and insulinemic reaction (GI), or total area under the curve PPGR, but it also sets mostly uniform PPGR for longer periods of time. Found that the required PPGR demonstrates fast, but limited initial increase in the concentration of glucose in craviola introduction to ensure rapid improvement of the energy state and prevent low levels of glucose for proper functioning and then stabilized for a longer period time. This is especially important for people suffering from hypoglycemic levels defined as glucose levels below 3.0 mm.

Nitroglicerina alpha-gluco-oligosaccharides characterized as having a GI below 60 then, as described above naglyadnye monosaccharides function as agents, releasing insulin to stimulate the seizure of glucose in the blood and, in addition, to reduce metabolic stress in the liver. Long-term increase in levels of glucose in plasma is especially important for people who can't eat regularly, and, for example, as the evening formula for infants.

Thus, the invention relates to nitroglicerina available carbohydrate composition containing the combination of (i) 5-60 wt.% one or more sugars in addition to glucose and fructose and (ii) 10-75 wt.% oligosaccharides containing glucose, having a length of 2-20 anhydromannose units containing at least one α-1,4-linked (that is, "not maltose type") anhydroglucose unit. It was found that the combination of monosaccharides, which are insulinotropic, i.e. stimulate the release of insulin without significant increase in levels of blood glucose and oligosaccharides, which also give a low postprandial response to glucose, leading to delayed supply of energy with a substantial uniform Rea is of glucose.

Used in this application sense, the term "nitroglycerine" means having the glycemic index (GI) is lower than 60, preferably less than 50; where GI is usually imply the relative rate of production of glucose in the blood compared with glucose (with a GI of 100 by definition). It is implied that the term "available carbohydrate" refers to a carbohydrate that is able to be cleaved by enzymes in the gastrointestinal tract. The products of digestion, or the carbohydrates are absorbed in the first part of the intestine, in particular the small intestine. In normal conditions these compounds or products of their digestion does not reach the large intestine. Available carbohydrates can also be defined according to the American Association of Cereal Chemists (AACC), as able to be internalized in the form of monosaccharides and metabolized by the body (person). Norms for food products typically require manufacturers to indicate on the label of a food product is the inclusion of it as digestible carbohydrates, and they are by definition bring 4 kilocalories per gram of material in the energy content of the product.

The term "sugars in addition to glucose and fructose" used in the present application contains any sense monosaccharide, which is aldose or ketosis or represents a pentose or Gex the memory. Examples include ribose, xylose, arabinose, ribulose, galactose, gulose, idose, mannose, sorbose and tagatose. The preferred sugars are ribose, galactose and mannose, and the most preferred is galactose. Preferably galactose is at least 25% of sugars in addition to glucose and fructose in the composition in accordance with the invention. The proportion of these sugars in addition to glucose and fructose, especially galactose, ribose and/or mannose in the composition in accordance with the invention is preferably 5-45 wt.%, more preferably 8-40 wt.%, most preferably 10-30 wt.% available carbohydrates.

Oligosaccharide comprising glucose, contain any and all oligosaccharide having a chain length from 2 to 20 anhydromannose units containing at least one anhydroglucose unit in any position. The term "anhydrous" is essentially used to denote sugar units, which are the links of the chain, regardless of their position in the chain and including the end of the unit. Preferably, at least half anhydromannose units oligosaccharide carbohydrate composition in accordance with the invention is anhydroglucose residues. More preferably, the oligosaccharides are the most anhydroglucose residues, most preferably they soda is subject to no more than one anhydromannose units except anhydroglucose.

The terms "anhydroglucose unit associated't 1,4-bonds", or "anhydroglucose unit, connected not by maltose type" is used to denote anhydroglucose unit (AGU), non-terminal or internal α-1,4-linked AGU's. This AGU connected in anomeric α-position with another anhydromannose unit in any position other than position 4 of a glucose residue or position 2 fructose units. In particular such AGU linked α1-position with the provisions of the 1-, 3-, 5-, or 6 other anhydromannose units, or also with position 2 another anhydroglucose units. As a less preferred alternative, or in addition, it can be linked in position 2-, 3-, or 6 with any position other anhydromannose units. For example, AGU's can be linked bonds α-1,1, α-1,2, α-1,3 and α-1,6. Therefore, maltose, sucrose and lactose are not included in these oligosaccharides. Can be one or more α-1,4 linked AGU at that time, as related in another way AGU's are also present, at least, with the same prevalence. Preferably, not more than 1 AGU linked bond α-1,4.

Examples of oligosaccharides include glucosyl-glucose disaccharides isomaltose (α-1,6), nigerose (α-1,3), koibito (α-1,2), trehalose (α, α-1,1), amygdalota (β-1,6), laminaribiose (β-1,3) and sophorose (β-1,2), heterogeneity Primavera is, allolactose, trehalose, turanose, maltulose, leucrose, isomaltulose (= palatinose), trisaccharide isomaltulose, Panose, colitis, etc., and higher homologues up to dikusarov such as isomaltulose, and even tosashimizu. Preferred are disaccharides and trisaccharide, the most preferred is trehalose, trehalose, palatinose, isomaltose and Panose. Containing glucose oligosaccharides can be obtained from natural sources or synthesized by the enzymatic isomerization of sugars such as sucrose, and several of them are commercially available. Oligosaccharides may also be obtained by enzymatic transglycosylation, for example, maltose to produce mainly α-1,6-linked rigopulos (isomalto-oligosaccharides). Oligosaccharides may have a straight chain or may be slightly branched. Additional examples include oligomerize and oligosaccharides of the type of alternan.

Not included in the available glucose component ii) are the so-called resistant maltodextrins, commercially available as, for example, Fibersol-2 and Nutriose. They have a predominantly fibrous structure and may partially contain a β-bond. These oligosaccharides fiber type can be estimated using the activity of intestinal hydrolysis powder is om rats, as described Mishima and others,J. Agric. Food Chem.2005,53,7257-7261. Sugars, which are not hydrolyzed in this rat intestinal test, is considered as not being available.

The preferred ratio of oligosaccharides (ii) in the compositions of the invention comprise 15-75 wt.%, more preferably 18-50 wt.%, of which preferably 10-60 wt.%, more preferably 15-45 wt.% on the basis of available carbohydrate composition consists of disaccharides (ii-a) such as trehalose, trehalose, palatinose, turanose, leucrose and isomaltose. Among them are particularly interesting disaccharides containing fructose, trehalose, palatinose, turanose and lacrosse and especially palatinose. Cleavage palatinose, for example, takes place only in the guts involving isomaltose.

Preferably, the components (i) and (ii)as defined above together constitute 25-100, preferably 28-75, most preferably 32-60 wt.% available carbohydrate composition, and, consequently, the number of other available carbohydrates (iii) is 0-75, preferably 25-72, most preferably 40-68 wt.%. In an alternative embodiment, the carbohydrate composition in accordance with the invention may contain (iii) 0-45 wt.%, preferably 10-40 wt.% other available carbohydrates.

Considering only the components (i) and (ii)that are present in the compositions in soo is according to the invention in the relative ratios of 5-60 and 10-75 mass parts, their ratio based on 100% (i) and-5/80-60/70 and (ii) 10/70-75/80, or (i) of 6.25 is 85.7 wt.% and (ii) 14,3-93,75%. The most preferred ratio is (i) 10/60-30/48 (16,7-62.5 wt.% and (ii) 18/48-50/60 (37,5-83,3 wt.%). Considering only disaccharides (ii-a), the relative ratio of (i) 5/65-60/70 (7,7-of 85.7 wt.%) and (ii-a) 10/70-60/65 (14,3-92,3 wt.%), most preferably (i) 10/55-30/45 (18,2-of 66.7 wt.%) and (ii-a) 15/45-45/55 (33,3-81,8 wt.%). These ratios relate in particular to the combination of galactose and palatinose. The combination of these specific specific monosaccharides and disaccharides, such as galactose and palatinose exhibit synergism in providing quick and delayed response to glucose.

Data other available carbohydrates are primarily contain (iii-a) sources of available glucose in the form of Monomeric glucose or easily accessible oligomers and polymers of glucose such as maltose, maltodextrins and not to be resistant starch; such a source of glucose contains exclusively or predominantly anhydroglucose units (>90%), linked by α-1,4 linkages. The availability of glucose from these sources may be determined by the Englyst method, etc. (Am. J. Clin. Nutr.1999, 69, 448-454): the ratio of the source of glucose, from which glucose is available within 120 minutes from the start of the test, expect to component (iii) of the compositions of the invention. The ratio, which is not proh who conduct this test, referred to as "fiber" for the purpose of the invention, and do not take into account in these 100% available carbohydrate composition as defined in this application. The available carbohydrate ratio source of glucose, from which glucose is available within 20 minutes from the start of the test, calculated as bystrodeistvie sources of glucose in accordance with the Englyst method.

Data available sources of glucose may be present at such a level that the overall glycemic index of the product remains lower than 75, preferably less than 60, especially below 50.

In addition, component (iii) may contain (iii-b) other mono - and disaccharides. For example, fructose may be present at the level of, for example, 4-25 wt.%, especially 6-18 wt.%, lactose can be present at, for example, from 0 to about 15 wt.% preferably 1-10 wt.%, sucrose from 0 to 5 wt.%. When using the above quantities of galactose and fructose in accordance with the invention do not contain galactose of the lactose and fructose portion of sucrose and palatinose.

When galactose is included in the formula, preferably the number bystroletnoe glucose 1.25-10, more preferably 1.5 to 6-fold amount by weight of free galactose. When free ribose, the amount by weight bystroletnoe glucose, in particular free glucose is 0.8-10 predpochtitelno 1-8-fold amount of free ribose. When the free fructose, weight bystroletnoe glucose to the weight of fructose is preferably in the range of 1: 0-0,12.

It is noted that to determine the composition of the invention, oligosaccharides, which are not covered by the components (ii) and (iii), as I believe, are not available carbohydrates; the same applies to the polysaccharides, which do not fall under the category of component (iii).

In addition, polyols such as mannitol, lactic, isomaltol (isomalt, 6-O-alpha-D-glyukopiranozil-D-sorbitol), etc. are not covered by the components (i), (ii) and (iii), which constitute 100% of the available carbohydrate composition. However, these polyols can be, for example, at the level of 0-20 wt.% available carbohydrate composition.

Also available carbohydrate composition can be used, for example, as an additive, or be part of a partial or complete food product, optionally containing proteins and/or lipids and/or fiber, minerals, vitamins, etc. the Composition may be a dry powder, or solid or semi-solid composition. Preferably, the food product is a liquid that is suitable for feeding through a tube or small SIPS. He has osmollnosti preferably 300 to 700, more preferably 330-600, most preferably 340-500 mOsm/l, and has a density of energy is between 0.6 and 2.0, the more preferably between 0.75 and 1.5 kcal/ml liquid product preferably contains the available carbohydrate fraction in accordance with the invention in quantities of 60-200, preferably 80-160, more preferably 100-140 g/l

Preference is given to the inclusion in the product non-viscous fibers. Viscous fibers, optionally in combination with other food components, as known to affect the rate of gastric emptying and the rate of digestion in the gastrointestinal tract. At the moment discovered that the fibers are preferably included in the product in accordance with the invention, should not behave as viscous fibers neither the product, nor in the gastrointestinal tract. Fiber, which can be used in accordance with the invention, mainly selected in this way and included in such concentrations that they exhibit low viscosity in the food composition. It appears that such fibers exhibit a low viscosity in vivo. Fibers that may be suitable for use, are transplantological (GOS) and vysokomineralizovannye rubbers, hydrolyzed the mannans, hydrolyzed arabani, hydrolyzed kilany, hydrolyzed beta-glucan, hydrolyzed fructans (fructose oligosaccharides, FOS), inulin and/or oligofructose. In addition, m is able to be used the so-called stable (nevereverever) fiber maltodextrin. Such non-viscous, usually soluble fiber is preferably used in an amount of 0-30 wt.%, preferably 4-24 wt.% available carbohydrate composition and, thus, with the expectation of outside of it 100%. On the energy basis of these fibers can be used at the level of, for example, 0-5 g, especially 0.4 to 4, in particular from 0.6 to 3 g per 100 kcal, and on the basis of liquid, 0-40, preferably 2-30, more preferably 4-25 g/l

In addition to these non-viscous soluble fibers may be poorly soluble or insoluble fibers such as resistant starch, cellulose and the like, for example at the level of 0-30 wt.%, preferably 4-20 wt.% available carbohydrate composition, or 0-4, especially 0.3 to 3 g per 100 kcal or 0-30, preferably 2-20 g/l

The total number without starch and fiber resistant starch is preferably in the range of 2-50, preferably 4-40, more preferably 6-30 g/l, the viscosity of the product is low to provide acceptable flow characteristics for drinking SIPS and for feeding through a tube. The viscosity, measured at 20°C at a shear rate of 100/sec, is 1-60, preferably 1,4-40, more preferably 1.8 to 30 MPa·s (for reference: the value for water is equal to one).

Food in accordance with the invention can further comprise an agent that stimulates insulin, preferred is part of a sulfonylurea, and/or anti-diabetic drug, preferably of biguanides and/or thiazolidinedione. If there is a sulfonylurea, a composition in accordance with the invention preferably contains it in an amount of 0.1-4 g per kg

Food composition in accordance with the invention may contain protein fraction. This protein fraction can be based on source of vegetable protein, to which may be added, at least one free amino acid, peptide or protein from an animal source. Protein fraction is preferably at 15-99,9 wt.%, preferably 20-95 wt.% derived from the plant species belonging to mind fabales, or leguminosae. Preferably proteins derived from one or more members of the group of soybeans (Glycine Max),peas (Pisum), bean (Phaseolus), fenugreek (Trigonella), lupins, lentils (Lens), peanuts (Arachis), tamarind, clover and alfalfa. Such protein composition additionally support the improvement of postprandial response to glucose and postprandial responses to insulin. Amino acids or peptides chosen so that they were rich in the amino acids that increase the nutritional value of protein fraction in General terms the requirements for essential amino acids. In particular, these amino acids are lysine, leucine and phenylalanine. It is notizie may include per 100 g of amino acids from 1.8 to 5 g methionine, and/or 4.5-9 g threonine, and/or 8,6 to 17 g of leucine and/or 5.5-9.5 g of Proline. Source of protein of animal origin is chosen in particular from milk proteins and liquefied protein from animal muscle or gidrolizirovanny proteins, like fish. Particularly preferred are milk proteins, especially whey proteins, and more specifically the whey proteins, which contain less than 40 wt.% and preferably less than 30 wt.% Kappa-casein or glycomacropeptide, calculated on the basis of proteins.

The amount of protein in foods is preferably 0.5 to 15 g, more preferably 1-10 and most preferably 2 to 7 g per 100 ml of product. The amount of energy calculated as the amount of energy, which provide protein, lipid and digestible carbohydrates, using Atwater factors (4, 9, 4, respectively) for each of them is for protein 10-30, preferably 14-28, most preferably 17-26 EN.% and for digestible carbohydrates 35-70, preferably 40 to 60, and most preferably 42-55 EN.%. The composition comprises 5-80, preferably 20-50 g/l protein fraction.

Food composition in accordance with the invention can additionally contain a fraction of lipid or fat. This lipid fraction contains oleic acid and essential fatty acids, linoleic acid and alpha-linoleic acid, but can the also contain conjugated linoleic acid and fatty acids with long chain omega-3, as eicosapentaenoic acid and decosahexaenoic acid. The fatty acids preferably contain less than 10 wt.% saturated fatty acids and less than 1 wt.% TRANS-fatty acids. The amount of lipid is 10-60, preferably 15-50, more preferably 31-46 g/L. Expressing the amount of lipid in the product, in EN.% using Atwater factors, the amount of lipid is 25-45, preferably 28-40 and most preferably 30-38 EN.% Lipids include triglycerides, diglycerides, monoglycerides, (lyso) phospholipids, sphingolipids and ceramides. Other components soluble in petroleum ether or hexane as cholesterol and other sterols, are not included in the calculations related to the lipid fraction.

In addition, the product may contain trace elements, vitamins, trace elements and minerals, which are known from the prior art, and equivalents carnitine, Inositol, taurine and other food components such as fragrances, dyes or production excipients. The amount of calcium and phosphorus (3) is also chosen so that it was within the range of 10-70, preferably 20-60 mg/100 ml the Ratio of calcium to phosphorus (3) is in the range 0.8 to 2, preferably from 1.1 to 1.9, more preferably from 1.3 to 1.8.

Available carbohydrate composition and nutritional composition in accordance with the invention is useful in maintaining n is scoi and long reaction for glucose in the blood and tissues after consumption and is particularly useful in cases of diabetic and/or insulin resistance. People who suffer from insulin resistance or extremely prone to it, for example, are seriously or critically ill patients, in particular palliative patients suffering from a severe form of cancer or HIV infection. Other groups of patients suffering from shortness of control PPGR, contain people who have been subjected to extensive surgery or subjected to other injured, malnourished people, in particular suffering from protein-energy malnutrition, people suffering from obesity, metabolic syndrome, syndrome X, hyperglycemia, hyperinsulinemia, dyslipidemia, hypertriglyceridemia and defibrinate, as well as large parts of the group of older people in Western societies. In addition, the product can be useful for people with an increased risk from the point of view of hereditary history of developing insulin resistance, PPGR in the blood of the mammal during the period of time that begins after 20 minutes - 4 hours after administration. Even more preferably maintain glucose concentration at steady state up to 3 hours, more preferably up to 2 hours after administration. Basically an even level of glucose, or PPGR means that the level of glucose in the blood does not change more than about 1.6 mm, and preferably less than 1.3, more preferably IU is of more than 1.0 mm, every 20 minutes during the above period after consumption.

In the case of diabetics glucose levels in the blood usually have between 4 mm and 15 mm. However, in the case of diabetics in a serious condition, can still be observed peak postprandial glucose concentrations above 15 mm. Under these circumstances, the food composition comprising a carbohydrate fraction in accordance with the invention, should be used for more than one meal and/or in combination with the introduction of the appropriate amount of insulin before eating food. In the case of adiabatically you can control the level of glucose in the blood even below 11 mm.

Preferably the levels of plasma glucose control between 5 and 8 mm for the above period of time, without the need to use with it large quantities of fibers, as they may cause gastrointestinal discomfort, and without replacement sources of glucose and other carbohydrates that require unrealistically high metabolic capacity in humans, or large amounts of lipids, which can hurt people with obesity or diabetes, as many people from the Indian subcontinent and several Caucasian families, for people who plan irregular eating, as athletes during a grueling workout, or people who trebuetsa.pojilae attention for longer periods of time, as students during training, or examination, or during meetings.

Thus, the available carbohydrate composition and nutritional composition in accordance with the invention can be used for the prevention and/or treatment of diabetes, insulin resistance, obesity, controlling postprandial response to glucose, metabolic syndrome, syndrome X, hyperglycemia, hyperinsulinemia, dyslipidemia, hypertriglyceridemia, defibrinate and/or disorders associated with major surgery or trauma in a mammal, by maintaining a basically stable level of glucose or physiologically acceptable profiles of lipids or cholesterol in the blood.

In addition, the products are effective in reducing the risk of acquisition and to reduce deterioration of the progress of several diseases that are often associated with rising levels of glucose in the blood, which include retinopathy, kidney disease and neuropathy. Can also be prevented diseases associated with the occurrence of premature products of glycation (AGE). The effectiveness of the product can be determined by measuring the levels of glycosylated molecules of hemoglobin (Hb1Ac) in the blood.

Example 1

There were prepared two liquid composition A and b for patients with diabetes, containing the following ingredients per 100 ml:

table width="90%" border="1" cellpadding="0" cellspacing="0" frame="all"> AInThe total number of protein4,75 (19 EN.%)4,75 (19 EN.%)The total number of lipidsof 3.78 (34 EN.%)of 3.78 (34 EN.%)The total number of available carbohydrates11,75 (47 EN.%)11,75 (47 EN.%)Galactose1,51,75Ribose0,3-Palatinose3,02,0Isomatic0,6-Isomalto-oligosaccharides-2,75Glucose1,51,7Maltodextrins3,02,2Unstable starch #1,00, Lactose *0,60,25Fructose0,150,2The total number of fibers2,02,0Galactooligosaccharide (GOS)0,9-Hydrolyzed guar-1,0Cellulose0,10,1Resistant starch ##1,00,9Vitamins, minerals, water++# Digestible (available) part commercial ingredient of resistant starch.
## Neparvarama part of the commercial ingredient of resistant starch.
* Lactose ingredient GOS.

Example 2

Were prepared liquid composition C and D (feeding SIPS or tube) for patients with diabetes, containing the following ingredients per 100 ml:

Energy:419 kJ (100 kcal)
The protein fraction:19,4 EN.%a 4.86 g
Whey protein enriched with α-lactalbumin2,43 g
Soy protein2,43 g
The fraction of lipids:34,2 EN.%3.80 g
Canola / sunflower seed (Canola HO blend 331)3,17
Sunflower oil HOA (Trisun 347)0.20 g
Nizkorodov rapeseed oil (Canola 338)0.20 g
Marinol0.10 g
Other0,13 g
Digestible fraction of carbohydrates: (see below)46.4 EN.%11,63 g
Fiber:2,00 g
Galactooligosaccharide1,00 g
Cellulose0.10 g
Nutrilose FM06 (neparvarama part)0.65 g
Resistant starch (neparvarama part)0.25 g


Na (37,5), K (100), Cl (37,5), Ca (47,0), P (37,5), Mg (23,0).

Trace elements:(in µg)

Fe (1600), Zn (1400), Cu (210), Mn (330), F (100), Mo (10,0), Se (7,5), Cr (12,0), I (13,0).

Vitamins:(in µg)

vitamin A (82 RE), carotenoids (200), vitamin D (1,2), vitamin E (2500 (α-TE)vitamin K (5,3),

vitamin B1 (400), vitamin B2 (200), Niacin (1800 NE), Pantothenic acid (800),

vitamin B6 (300), folic acid (38), vitamin B12 (0,65), Biotin (6,5), vitamin C (15,0), choline (37).

Compositions C and D differ in the fraction of digestible carbohydrates as shown below:

The full amount of available carbohydrate11,6311,63
Alternan, DP 102,00-
Cleargum (manioc starch)0,802,80
Digestible part of the product resistant starch0,250,25
Digestible part of Nutriose FM060,120,12
Other *1,561,06
* Lactose ingredient GOS.

1. Nitroglicerina composition, available carbohydrates, containing the following components:
(i) 5-60 wt.% one or more monosaccharides selected from monosaccharides other than glucose and fructose, in particular galactose, ribose and mannose;
(i) 10-75 wt.% oligosaccharides, having a length of 2-20 anhydromannose units, at least half of which is anhydroglucose remains bound in the α-position with 1-, 3-, 5 - or 6-position of another anhydromannose unit; and component (ii) contains 10-60 wt.% one or more oligosaccharide selected from trehalose, palatinose, turanose and leucrose and
(iii) 0-75 wt.% other available carbohydrates.

2. The carbohydrate composition according to claim 1, in which the components (i) and (ii) are 28-75, preferably 32-60 wt.% song.

3. The carbohydrate composition according to claim 1, containing:
(i) 8-40 wt.%, preferably 10-30 wt.% of one or more monosaccharides selected from galactose, ribose and mannose, preferably galactose.

4. The carbohydrate composition according to any one of claims 1 to 3, in which component (ii) contains 15-45 wt.% palatinose.

5. The carbohydrate composition according to any one of claims 1 to 3, in which component (iii) contains 4-25 wt.% fructose.

6. The carbohydrate composition according to any one of claims 1 to 3, in which component (iii) contains 5-40 wt.% bystroletov sources of glucose that is selected from glucose, maltooligosaccharides and digestible starch.

7. The carbohydrate composition according to any one of claims 1 to 3, containing 0.4 to 0.8 times the fully dry weight carbohydrate components (i)-(iii) bystroletnoe glucose or glucose slow release.

8. The carbohydrate composition according to any one of claims 1 to 3, the soda is containing 5/65-60/70 parts by weight of galactose and 10/70-60/65 parts by weight of palatinose, preferably 10/55-30/45 parts by weight of galactose and 15/45-45/55 parts by weight of palatinose.

9. Food composition comprising the composition of available carbohydrates according to any one of claims 1 to 8, optionally containing proteins and/or lipids.

10. The food composition of claim 8 additionally containing 2-30 wt.%, on the basis of the complete dry weight carbohydrate fraction of components i)to iii) in the food composition, dietary fiber.

11. The food composition according to any one of p or 9, which is the liquid composition, and available carbohydrate composition is 35-70 EN.% food composition.

12. The use of carbohydrate composition according to any one of claims 1 to 8 to obtain a food or pharmaceutical composition for the treatment of diabetes, obesity, insulin resistance, or for the postprandial response to glucose.


Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: in claimed invention described are phenoxiacetic acids of formula I: where X is selected from S and SCH2, X1 represents O, R1 represents C1-C6alkyl, R2 represents -C≡C-R2a, R2a represents C1-C4alkyl, substituted with morpholinyl, R3 is selected from chlorine and methyl, R4a represents H, R4b represents H, R4c represents H, R5a represents H, R5b represents H, R5c represents H, R5d represents H and R5e represents H, and pharmaceutical compositions containing them.

EFFECT: phenoxiacetic acids are PPAR-δ activators and can be used for treatment of mediated by them conditions.

6 cl, 48 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel sulphonamidethiazole pyrimidine derivatives of formula (I)

, which are glucokinase activators or to their enantiomers, mixture of enantiomers or pharmaceutically acceptable salts. The invention also relates to a pharmaceutical composition based on the novel compounds, use of the compounds to prepare a medicinal agent and to a method of activating glucokinase. In formula (I) R1 denotes (C1-C10)alkoxy, R2 denotes (C3-C6)cycloalkyl, R3 denotes hydrogen, and values of substitutes R4 and R5 are given in the formula of invention.

EFFECT: more effective use of the compounds.

33 cl, 166 ex

FIELD: chemistry.

SUBSTANCE: disclosed compounds can be used as a medicinal agent which modulates PPARδ (peroxisome proliferator-activated receptor δ). In formula I

, p is equal to 1; L2 is selected from a group which includes -XOX- and -XSX-, where X is independently selected from a group which includes a bond and C1-C4alkylene; R13 is selected from a group which includes halogen, C1-C6alkyl; R14 is selected from a group which includes -XOXC(O)OR17 and -XC(O)OR17, where X denotes a bond or C1-C4alkylene and R17 denotes hydrogen; R15 and R16 are independently selected from a group which includes -R18 and -YR18, where Y is selected from a group which includes C2-C6alkenylene, and R18 is selected from a group which includes C6-C10aryl, pyridinyl, pyrimidinyl, quinolinyl, benzo[b]furanyl, benzoxazolyl, 1,5-benzodioxanyl, 1,4-benzodioxanyl and 3,4-dihydro-2H-benzo[b][1,4]dioxepin; where any of phenyl, pyridinyl, pyrimidinyl, benzoxazolyl in R18 is independently substituted with 1-2 radicals, independently selected from a group which includes halogen, C1-C6alkyl, C2-C7alkenyl, C1-C6alkoxy group, halogen-substituted C1-C6alkyl, halogen-substituted C1-C6alkoxy group, C3-C12cycloalkyl, phenyl, morpholinyl, pyrrolidinyl, piperidinyl, -XNR17R17, -XC(O)NR17R17, -XC(O)R19 and -XOXR19, where X denotes a bond or C1-C4alkylene; R17 is selected from a group which includes C1-C6alkyl, and R19 is selected from a group which includes C3-C12cycloalkyl, piperidinyl and phenyl. The invention also relates to use of the disclosed compounds to prepare a medicinal agent which modulates PPARδ activity, a pharmaceutical composition having PPARδ activity modulating properties, which contains a therapeutically effective amount of the disclosed compound and to use of the pharmaceutical composition in preparing a medicinal agent which modulates PPARδ activity.

EFFECT: improved properties of compounds.

10 cl, 1 tbl, 69 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to development of a pharmaceutical composition for blood sugar and fat control, to a method of manufacturing of said pharmaceutical composition, to administration thereof. The pharmaceutical composition contains the following Chinese herbs or their extracts in mass portions: 5-17 privet fruits (Ligustri lucidui), 3-12 locoweed roots (Radix Astragali Mongolia), 1-5 gold-thread rhizomes (Rhizoma Coptidis), 1-5 lychee seeds (Semen Litchi), optionally 1-6 laminarias (Thallus Laminariae Japonicae) and 1-6 turmeric rhizomes (Rhizoma Curcumae Longae).

EFFECT: manufacturing of the pharmaceutical composition to be applied for treating diabetes.

10 cl, 27 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacy, namely: to the development of a herbal drug exhibiting anorectic, hypoglycemic and hypolipidemic action. Object of the invention is worked out by developing an anorectic, hypoglycemic, hypolipidemic drug which represents an aqueous extract of black and brown leaves of Bergenia crassifolia collected after 1-2 winter stays which are dried at temperature 35-45°C before extraction to constant weight and crushed.

EFFECT: developing the herbal drug exhibiting hypoglycemic, hypolipidemic action and ability to suppress appetite with no by-effects.

1 cl, 5 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, and relates to peroral transmucosal pharmaceutical compositions, containing metformin or its pharmaceutically acceptable salt, in presence of at least one absorption intensifier, selected from alkylsulfate of alkaline metal, glycerin, bile acid or salt of bile acid, and also to methods for application of such compositions for treatment of diabetes in an individual, to method of compositions preparation.

EFFECT: composition provides for high bio-availability of metformin in an individual and fast therapeutic effect.

24 cl, 5 ex, 1 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: this invention relates to cocrystalline form of (1S)-1,5-anhydro-1-[3-(1-benzothiene-2-ylmethyl)-4-fluorophenyl]-D-glucitol (compound A) with L-proline. Proposed cocrystalline form is a promising anti-diabetes medicine.

EFFECT: cocrystalline form of compound is characterised with constant composition, improved stability in storage, and also low hygroscopicity, and is suitable for use as crystalline medicinal substance to produce pharmaceutical preparations.

11 cl, 1 ex, 2 tbl, 10 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-cyclopropyl-1 -{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate of formula:

. The invention also relates to salts and solvates of the said compound, a method of producing said compound, a pharmaceutical agent having angiotensin II antagonist activity, based on said compound.

EFFECT: compound can be used in medicine to prevent and treat blood circulatory system diseases.

18 cl, 1 dwg, 8 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula

and pharmaceutically acceptable salts thereof, where substitutes R1-R4 are as defined in claim 1. Said compounds have 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) enzyme inhibiting activity.

EFFECT: compounds can be used in form of a pharmaceutical composition.

15 cl, 1 tbl, 94 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new imidazopyrazines of formula where Q1 and R1 have the values specified in the patent claim, and to their pharmaceutically acceptable salts showing IGF-1R enzyme inhibiting activity and applicable for treatment and/or prevention of various diseases and conditions which are sensitive to tyrosine kinase inhibition.

EFFECT: preparation of the compounds showing IGF-1R enzyme inhibiting activity.

27 cl, 294 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely, to efferent methods in surgery, and can be used in treating peritonitis patients. That is ensured by prolonged venovenous hemofiltration. In 2 hours after the procedure started, through a catheter inserted in a subclavian vein or a abdominal aorta with using a peristaltic pump for 15 minutes 250 ml of HyperHAES solution is introduced.

EFFECT: method allows higher effectiveness of detoxification ensured by an effect of endotoxin redistribution in a vascular bed from an interstitial space owing to introducing the hydroxyethyl starch solution followed by endotoxin elimination from the vascular bed by hemofiltration.

1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: there is disclosed an application of complex iron (III) compounds with poly-maltha, hydrogenated dextrins or maltodextrin oxidation products for reparing an oral drug for iron deficiencies in patients suffering a chronic inflammatory intestinal disease, particularly Crohn's disease and nonspecific ulcerative colitis. When having been administered, the declared drugs have not invoked oxidative stress in contrast to iron sulphate therapy.

EFFECT: declared compounds are well tolerable, provide high compliance.

8 cl, 1 dwg, 3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: first hemodilution is performed by exfusion of undiluted autoblood. As volume-substituting component, applied is autoplasm, prepared by method of intermittent plasmapheresis at gestation term from 32 to 38 weeks. After achievement of surgical hemostasis reinfusion of prepared undiluted autoblood in amount 5-10 ml/kg of body weight is carried out. Method makes it possible to provide adequate compensation of operation blood loss by stabilisation of blood coagulation potential and restoration of erythrocyte population in blood stream.

EFFECT: prevention of risk of developing complications in case of predicted blood loss in course of delivery due to following specific sequence of taken measures.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to anesthesiology and resuscitation, and can be used in states accompanied by massive blood loss. For this purpose, 5 and 3 days prior to a surgery, autoblood is sampled in amount 10 % of circulating blood volume (CBV) in each sampling to be divided on plasma and erythrocyte concentrate. For 5 preoperative days, iron preparations are administered in a therapeutic dose. Also, the surgery is preceded with analysing patient's fluid deficiency. 40 minutes prior to the surgery, 12.5 % dicynone 500 mg, one volume of autoplasma are introduced, and infusion of a rated dose of 5 % glucose and 6 % hydroxyethyl starch (HES) 500 ml is started. If the intraoperative blood loss is suggested to be 15-30 % of the CBV, additionally 6 % HES 250 ml, prednisolone in dosage 2-4 mg/kg of body weight and one volume of erythrocyte concentrate are administered. If the estimated intraoperative blood loss exceeds 30 % of the CBV, the second volumes of autoplasma and erythrocyte concentrate, another introduction of dicynone in the same dosage, 6 % HES 250 ml, prednisolone in dosage 7 - 10 mg/kg of body weight are required. Within 30 and 60 minutes after the surgery, dicynone is injected in the same dosage. 5 hours after the surgery, filter drainage fluid is returned. 6 hours after the surgery, coagulation time is determined, and if observing no hypocoagulation, Clexane is introduced in a preventive dose.

EFFECT: method allows to provide early activation of erythropoiesis combined with improved erythrocyte morphology and blood haemostatic function, considerably reduced risk of complications connected with massive transfusion of donor blood products, as well as prevented edema of interstitial spaces and development of multiple-organ-failure syndrome due to maintained effective transcapillary exchange.

5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicinal agents and to application of benzoic acid and/or its sodium salt in combination with saccharide (saccharides) as active components to make vaginal composition, to stimulate growing number of gram-positive bacilli and production of acids in vagina, in case gram-positive bacilli in vagina are scarce, and vagina acidity is far too weak, and to inhibit production of acids into vagina, in case of high number of gram-positive bacilli in vagina and excessive acidity of vagina, by maintenance of vaginal secretion pH value in the range from 3.5 to 4.5. Also vaginal composition is described, as well as method to control microflora and acidity of vagina.

EFFECT: development of medicinal agent to stimulate increasing amount of gram-positive bacilli and production of acids in vagina.

13 cl, 3 tbl, 36 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, and concerns preparation of a metal of arabinogalactan. The method for preparing the metal derivative of arabinogalactan by the reaction of arabinogalactan and a with a cys-dichlorodiamminplatinum (II) solution in heating on a water bath for 15 minutes, filtering and upsetting in an alcohol, with the reaction conducted in a neutral medium.

EFFECT: method allows preparing a metal polymer of arabinogalactan exhibiting higher water solubility and lower toxicity.

4 ex

Infant food // 2404785

FIELD: food industry.

SUBSTANCE: invention relates to food and pharmaceutical industry. Infant food composition, containing protein, fats, carbohydrates, nucleotides, nucleosides and nonprotein negatively charged polygalacturonic acid taken at in certain amounts. Application of composition for production of composition for infant feeding. Application of nutrient composition to produce composition for treatment and/or prophylactics of inflammatory disease, diarrhea, eczema and/or atopic dermatitis of a baby.

EFFECT: nutrient composition efficiently imitates protective action of human milk, in particular, against allergies and infections.

9 cl, 4 ex

Eye medicinal film // 2404779

FIELD: medicine.

SUBSTANCE: invention relates to medicine, to the field of ophthalmology. Eye film contains polyvinyl alcohol, arabinogalactan, levofloxacin at a certain ratio of components. Invention expands spectrum of therapeutic action of film by giving it immonomodulatory and membrane-acting properties.

EFFECT: invention provides for prolonged action of eye film.

2 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to method for production of complex immunotropic preparation for animals, including mixing 90 wt parts of 0.2-0.3 % agar suspension, 2.5 wt parts of concentrate of purified polysaccharide complex, 3.5 wt parts (-)2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]-thiazole hydrochoride, 0.2 wt parts of formalin and 7.0 wt parts of antibiotic ceftriaxone.

EFFECT: increased non-specific resistance and immunogenesis, prophylactics and treatment of inflammatory processes in animals.

3 tbl, 5 ex

FIELD: food industry.

SUBSTANCE: invention is related to production of an inuline-containing solution for food and medical purposes. The method includes washing and milling girasol/sunflower, its treatment in a microwave field until inactivation of native enzymes, extraction with acid water at preset parametres of the process, concentration of the extract through reverse osmosis, photosterilisation and packaging under aseptic conditions.

EFFECT: method enables to provide for a high yield of inuine in the target product combined with reduced chromatic level of the latter, reduction of energy costs and provision for the target product storage life being at least 1 year without considerable modification of its consumer and technological properties.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oligosaccharide, suitable for vaccine against meningitis A, which includes first mannose unit, which has spacer in alfa-configuration in C-1, where said spacer is able to conjugate with protein, and bound to second mannose unit by 1,6-bond, which binds C-6 of first unit with C-1 of second unit, 1,6-bond including phosphonate. Invention also relates to methods of obtaining oligosaccharide and improved methods of obtaining mannose derivative, suitable for obtaining immunogenic oligosaccharide. Invention also relates to pharmaceutical composition for induction of immune response, immunogenic composition, capable of inducing formation of protective antibodies against meningitis A and vaccine against meningitis A, which include oligosaccharide.

EFFECT: obtained glycoconjugates have C-phosphonate bond, which is much more stable than natural phosphodiester bonds, as well as higher immunologic activity.

51 cl, 4 dwg, 3 tbl, 16 ex